Effects of infant formula containing milk fat on the parameters of digestion

I1. Good general health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination;

I2. Age between birth and 2 months (limits included);

I3. Full term infant (37 weeks ≤ gestational age ≤ 42 weeks);

I4. 2500g ≤ birth weight ≤ 4500g;

I5. Exclusively bottle-fed for at least one week at time of enrolment and only if parent(s) / guardian(s) independently decided before enrolment to exclusively bottle-feed;

I6. Having obtained both parent’s or legally authorized representative’s written consent in accordance with legal requirements;

I7. Parent(s) / guardian(s) who agree not to start complementary feeding during study period;

I8. Two legal representatives (parent(s) / guardian(s)) who are capable of and willing to comply with the protocol;

I9. At least one of the legal representatives is affiliated with a social security scheme.

E1. Significant pre-natal and/or serious post-natal disease (per investigator’s medical decision);

E2. Subject under antibiotics treatment at time of enrolment or infant who was under antibiotics treatment until one week prior to V0;

E3. With a known or suspected cow milk protein allergy (CMPA) or family medical history of CMPA;

E4. With a known intolerance or hypersensitivity to any of the study products’ ingredients;

E5. Exposure to probiotics (any product);

E6. Minor parent(s) (below 18 years old);

E7. Infants whose parent(s) / guardian(s) cannot be expected to comply with study procedures;

E8. Currently participating or having participated in another clinical trial since birth;

E9. Parent(s) / guardian(s) presenting a psychological or linguistic incapability to sign the informed consent;

E10. Parent(s) / guardian(s) impossible to contact in case of emergency.